摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-methoxybenzyl)-2-oxo-5-ethoxy-pyrrolidine | 119984-49-5

中文名称
——
中文别名
——
英文名称
1-(4-methoxybenzyl)-2-oxo-5-ethoxy-pyrrolidine
英文别名
(+-)-5-Ethoxy-1-((4-methoxyphenyl)methyl)-2-pyrrolidinone;5-ethoxy-1-[(4-methoxyphenyl)methyl]pyrrolidin-2-one
1-(4-methoxybenzyl)-2-oxo-5-ethoxy-pyrrolidine化学式
CAS
119984-49-5
化学式
C14H19NO3
mdl
——
分子量
249.31
InChiKey
MFBSNWYKMJYOMX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    415.5±45.0 °C(Predicted)
  • 密度:
    1.13±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    18
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    38.8
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    5-乙氧基-2-吡咯烷酮4-甲氧基氯苄氢氧化钾四丁基溴化铵 作用下, 以 四氢呋喃 为溶剂, 反应 2.0h, 以71%的产率得到1-(4-methoxybenzyl)-2-oxo-5-ethoxy-pyrrolidine
    参考文献:
    名称:
    Amnesia-reversal activity of a series of 5-alkoxy-1-arylcarbonyl-2-pyrrolidinones and 5-alkoxy-1-arylmethyl-2-pyrrolidinones
    摘要:
    A series of 5-alkoxy-1-arylcarbonyl-2-pyrrolidinones (1-27) were prepared by condensation of arylcarbonyl chlorides with 5-alkoxy-2 pyrrolidinones in the presence of butyl lithium in tetrahydrofuran. Alkylation of these intermediates with substituted benzyl bromides or chlorides, under solid/liquid phase-transfer conditions (KOH/Bu4NBr) in tetrahydrofuran, yielded 5-alkoxy-1-arylmethyl-2-pyrrolidinones (28-48). In the first series, the compounds with a 5-n-pentyloxy group had maximal ECS-induced amnesia reversing activity in mice, and in the second series, those with a 5-n-octyloxy group. In both series, substitutions on the phenyl ring had detrimental effects. The two most promising compounds 1-benzoyl-5-n-pentyloxy-2-pyrrolidinone (14) and 1-benzyl-5-n-octyloxy-2-pyrrolidinone (37) were more potent than piracetam and aniracetam and active over broader dose ranges: 50-200 and 50-400 mg/kg, po. Both compounds also reversed scopolamine-induced amnesia in mice, from 50 to 400 mg/kg, po (14) and from 100 to 400 mg/kg, po (37). Finally, 37 showed remarkable activity in protecting the mouse brain against chemically induced hypoxia, with a minimal effective dose of 50 mg/kg, ip, or 100 mg/kg, ip, in NaNO2- or KCN-induced hypoxia.
    DOI:
    10.1016/0223-5234(91)90102-s
点击查看最新优质反应信息

文献信息

  • Derivatives of 1-benzyl-2-oxo-5-alkoxy-pyrrolidine, and medicament
    申请人:Roussel Uclaf
    公开号:US04882350A1
    公开(公告)日:1989-11-21
    Compounds useful in the treatment of patients suffering from intellectual or nervous asthenias, memory failures, senescence or metal strain of the formula (I) ##STR1## in which R' represents hydrogen, linear, branched or cyclic alkyl containing up to 12 carbon atoms, alkenyl containing from 2 to 8 carbon atoms, acyl containing from 1 to 6 carbon atoms or aralkyl containing from 7 to 15 carbon atoms and R represents aryl containing up to 14 carbon atoms, possibly substituted, or a mono- or polycyclic heterocyclic aromatic radical possibly substituted, provided that if R is unsubstituted phenyl, R' does not represent methyl or ethyl; also therapeutic compositions containing those compounds and method of use.
    本发明涉及一种用于治疗患有智力或神经虚弱症、记忆力减退、衰老或心理应力的化合物,其化学式为(I)##STR1##其中R'代表氢、线性、支链或含有高达12个碳原子的环烷基,含有2至8个碳原子的烯基,含有1至6个碳原子的酰基或含有7至15个碳原子的芳基烷基,而R代表含有高达14个碳原子的芳基,可能被取代,或可能被取代的单环或多环杂环芳基基团,但如果R为未取代的苯基,则R'不代表甲基或乙基;还包括含有这些化合物的治疗组合物和使用方法。
  • Nouveaux dérivés de 1-benzyl 2-oxo 5-alcoxy pyrrolidine, leur procédé de préparation, leur application comme médicaments et les compositions les renfermant
    申请人:ROUSSEL-UCLAF
    公开号:EP0296978B1
    公开(公告)日:1991-09-11
  • US4882350A
    申请人:——
    公开号:US4882350A
    公开(公告)日:1989-11-21
  • Amnesia-reversal activity of a series of 5-alkoxy-1-arylcarbonyl-2-pyrrolidinones and 5-alkoxy-1-arylmethyl-2-pyrrolidinones
    作者:E Toja、C Gorini、C Zirotti、F Barzaghi、G Galliani
    DOI:10.1016/0223-5234(91)90102-s
    日期:1991.6
    A series of 5-alkoxy-1-arylcarbonyl-2-pyrrolidinones (1-27) were prepared by condensation of arylcarbonyl chlorides with 5-alkoxy-2 pyrrolidinones in the presence of butyl lithium in tetrahydrofuran. Alkylation of these intermediates with substituted benzyl bromides or chlorides, under solid/liquid phase-transfer conditions (KOH/Bu4NBr) in tetrahydrofuran, yielded 5-alkoxy-1-arylmethyl-2-pyrrolidinones (28-48). In the first series, the compounds with a 5-n-pentyloxy group had maximal ECS-induced amnesia reversing activity in mice, and in the second series, those with a 5-n-octyloxy group. In both series, substitutions on the phenyl ring had detrimental effects. The two most promising compounds 1-benzoyl-5-n-pentyloxy-2-pyrrolidinone (14) and 1-benzyl-5-n-octyloxy-2-pyrrolidinone (37) were more potent than piracetam and aniracetam and active over broader dose ranges: 50-200 and 50-400 mg/kg, po. Both compounds also reversed scopolamine-induced amnesia in mice, from 50 to 400 mg/kg, po (14) and from 100 to 400 mg/kg, po (37). Finally, 37 showed remarkable activity in protecting the mouse brain against chemically induced hypoxia, with a minimal effective dose of 50 mg/kg, ip, or 100 mg/kg, ip, in NaNO2- or KCN-induced hypoxia.
查看更多